Management of the adult with non-chemotherapy-induced neutropenia
- Nancy Berliner, MD
Nancy Berliner, MD
- Professor of Medicine
- Harvard Medical School
- Chief, Division of Hematology
- Brigham and Women's Hospital
The management of adults with neutropenia can be challenging because the number of neutrophils circulating in the peripheral blood (reflected in the absolute neutrophil count [ANC]) is not always predictive of the individual's ability to respond to infection. This topic will discuss the management of the adult patient with non-chemotherapy-induced neutropenia (ie, neutropenia that is not the result of chemotherapy or hematopoietic cell transplant [HCT]).
The diagnostic evaluation of adults with non-chemotherapy-induced neutropenia is presented separately. (See "Approach to the adult with unexplained neutropenia".)
The management of children with neutropenia is also discussed separately. (See "Evaluation and management of fever in children with non-chemotherapy-induced neutropenia" and "Fever in children with chemotherapy-induced neutropenia" and "Congenital neutropenia" and "Cyclic neutropenia" and "Overview of neutropenia in children and adolescents".)
Fever in a patient with neutropenia due to chemotherapy, HCT, or bone marrow suppression from any cause is a medical emergency because such patients are at risk of sepsis and death from overwhelming infection. The management of chemotherapy-induced neutropenia and chemotherapy-induced neutropenia with fever are presented separately. (See "Risk assessment of adults with chemotherapy-induced neutropenia" and "Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults" and "Risk of infection in children with fever and non-chemotherapy-induced neutropenia" and "Overview of neutropenic fever syndromes".)
DEFINITION OF NEUTROPENIA
The definition of neutropenia varies from institution to institution. Neutropenia is usually defined (and defined herein) as an absolute neutrophil count (ANC) <1500 cells/microL (<1.5 x 109/L) in an adult. The ANC is equal to the product of the white blood cell (WBC) count and the percentage of neutrophils from the WBC differential (calculator 1). (See "Approach to the adult with unexplained neutropenia", section on 'Terminology and definition of neutropenia'.)To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:
- Kyle RA. Natural history of chronic idiopathic neutropenia. N Engl J Med 1980; 302:908.
- Dale DC, Guerry D 4th, Wewerka JR, et al. Chronic neutropenia. Medicine (Baltimore) 1979; 58:128.
- Pincus SH, Boxer LA, Stossel TP. Chronic neutropenia in childhood. Analysis of 16 cases and a review of the literature. Am J Med 1976; 61:849.
- Newburger PE, Dale DC. Evaluation and management of patients with isolated neutropenia. Semin Hematol 2013; 50:198.
- Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64:328.
- Dale DC, Bonilla MA, Davis MW, et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993; 81:2496.
- Kuritzkes DR, Parenti D, Ward DJ, et al. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group. AIDS 1998; 12:65.
- Gurwith M, Brunton JL, Lank B, et al. Granulocytopenia in hospitalized patients. II. A prospective comparison of two antibiotic regimens in the empiric therapy of febrile patients. Am J Med 1978; 64:127.
- Single protective isolation in patients with granulocytopenia. N Engl J Med 1981; 304:1493.
- Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25:247.
- Roe TF, Coates TD, Thomas DW, et al. Brief report: treatment of chronic inflammatory bowel disease in glycogen storage disease type Ib with colony-stimulating factors. N Engl J Med 1992; 326:1666.
- Bonilla MA, Dale D, Zeidler C, et al. Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias. Br J Haematol 1994; 88:723.
- Hammond WP 4th, Price TH, Souza LM, Dale DC. Treatment of cyclic neutropenia with granulocyte colony-stimulating factor. N Engl J Med 1989; 320:1306.
- Wright DG, Kenney RF, Oette DH, et al. Contrasting effects of recombinant human granulocyte-macrophage colony-stimulating factor (CSF) and granulocyte CSF treatment on the cycling of blood elements in childhood-onset cyclic neutropenia. Blood 1994; 84:1257.
- Manfredi R, Mastroianni A, Coronado O, Chiodo F. Recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF) in leukopenic patients with advanced HIV disease. J Chemother 1996; 8:214.
- Lehrnbecher T, Welte K. Haematopoietic growth factors in children with neutropenia. Br J Haematol 2002; 116:28.
- Andrès E, Kurtz JE, Martin-Hunyadi C, et al. Nonchemotherapy drug-induced agranulocytosis in elderly patients: the effects of granulocyte colony-stimulating factor. Am J Med 2002; 112:460.
- Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 1997; 25:551.
- DEFINITION OF NEUTROPENIA
- INFECTIOUS RISK STRATIFICATION
- Overview of risk stratification
- Bone marrow evaluation
- Clinical features
- Counseling regarding infectious risk
- PATIENTS WITH INADEQUATE BONE MARROW RESERVE
- Overview of infectious risk
- Preventing infection
- - Overview of infection prevention
- - Myeloid growth factors to reduce infectious risk
- - Hematopoietic cell transplantation
- Treatment of infection
- - Overview of treatment
- - Specific pathogens and sites of infection
- - Antimicrobials
- - Myeloid growth factors to treat infection
- - Granulocyte transfusions
- - Monitoring response to treatment
- PATIENTS WITH ADEQUATE BONE MARROW RESERVE
- Monitoring asymptomatic individuals
- Treatment of infection
- SUMMARY AND RECOMMENDATIONS